Telo Genomics Corp. has announced the presentation of new performance data for its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) at the International Myeloma Society (IMS) 2024 annual meeting in Brazil. The data demonstrates the test's ability to more accurately stratify SMM patients, potentially leading to more informed treatment decisions.
The analysis, which compared TeloViewSMM's results with the 20-2-20 scoring model currently included in international guidelines for SMM prognosis, showed that TeloViewSMM outperformed the existing model in identifying both true positive (high-risk) and true negative (low-risk) patients. The study was conducted on a cohort of 160 SMM patients.
Improved Risk Stratification in SMM
The presented results indicate that TeloViewSMM offers a significant improvement over previous attempts to stratify SMM patients according to their risk of progression to full-stage multiple myeloma. The test exhibits high sensitivity and specificity, making it a viable prognostic tool for SMM management.
Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the National Comprehensive Cancer Network (NCCN) Myeloma Committee, presented the analysis at IMS 2024. Dr. Kumar, who is also Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies, emphasized the importance of the test in addressing a critical unmet need in SMM patient care.
Addressing Unmet Needs in SMM Management
SMM, a precursor to multiple myeloma, is characterized by elevated M-protein biomarkers. TeloViewSMM stratifies these patients into high-risk and low-risk categories, helping clinicians determine the most appropriate course of action. High-risk patients may benefit from immediate treatment intervention, potentially leading to a cure due to recent advancements in treatment regimens. Conversely, low-risk patients can be monitored using TeloViewSMM, avoiding unnecessary and debilitating treatments.
Non-Invasive Monitoring
A key advantage of TeloViewSMM is its non-invasive nature. The test can be performed periodically using a simple blood draw, making it a convenient option for monitoring disease progression. Demographic studies suggest that SMM affects approximately 0.5% of the population over 40, representing a significant market opportunity for TeloViewSMM, potentially encompassing over 500,000 tests per year.
